Hereditary haemolytic anaemias represent the most prevalent group of genetic disorders worldwide.
A new Therapeutics paper provides a comprehensive overview of pyruvate kinase activators as a novel therapeutic approach for hereditary haemolytic anaemias: spkl.io/6010ALnP8